source
- Apnimed targets up to $160 million IPO to fund sleep‑apnea drug AD109Apnimed, a sleep‑specialist biotech, announced plans for an initial public offering that could raise up to $160 million in gross proceeds. The company will sell 10 million shares at $14‑$16 each,…
- Pharma deals in China face heightened IP risk under U.S. BIOSECURE ActPharma companies are increasing licensing activity in China, but experts say patent attorneys must now factor in the geopolitical implications of the BIOSECURE Act. The legislation seeks to compil…